CDK8 Inhibition Releases the Muscle Differentiation Blockade in Fusion-driven Alveolar Rhabdomyosarcoma [CUT&RUN]
ChIP-seq / ATAC-seq (genome binding and open chromatin) · human · 50 samples
- What it is
- ChIP-seq / ATAC-seq (genome binding and open chromatin)Where proteins bind the genome, or which regions are open and active.
- Organism
- Homo sapiens (human)
- Topic
- Soft tissue sarcomaThis series is part of our curated briefing on it.
- Samples
- 50 samples: 23 conditions, mostly in duplicateGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
Read the full summary ↓
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE303151_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: Look for peak files (.bed, .narrowPeak) and signal tracks (.bigWig) among the supplementary files; the raw reads are on ENA.
Also filed as BioProject PRJNA1294235 and SRA study SRP602524. Searching any of these in the dataset finder brings you back here.
Supports a between-group comparison across 46 samples.
How we read this: 23 replicated groups read from 50 sample titles; they account for 46 of them. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM9118988 C&R_Rh30_P3F_rep1
- GSM9118989 C&R_Rh4_P3F_rep1
- GSM9118990 C&R_Rh30_CDK8_rep1
- GSM9118991 C&R_Rh4_CDK8_rep1
- GSM9118992 C&R_Rh30-P3F-FKBP_P3F-HA_DMSO_rep1 C&R_Rh30-P3F-FKBP_P3F-H…
- GSM9118993 C&R_Rh30-P3F-FKBP_P3F-HA_DMSO_rep2 C&R_Rh30-P3F-FKBP_P3F-H…
- GSM9118994 C&R_Rh30-P3F-FKBP_P3F-HA_BI1347-24hr_rep1 C&R_Rh30-P3F-FKBP_P3F-H…
- GSM9118995 C&R_Rh30-P3F-FKBP_P3F-HA_BI1347-24hr_rep2 C&R_Rh30-P3F-FKBP_P3F-H…
- GSM9118996 C&R_Rh30-P3F-FKBP_P3F-HA_BI1347-72hr_rep1 C&R_Rh30-P3F-FKBP_P3F-H…
- GSM9118997 C&R_Rh30-P3F-FKBP_P3F-HA_BI1347-72hr_rep2 C&R_Rh30-P3F-FKBP_P3F-H…
- GSM9118998 C&R_Rh30_SIX4_DMSO_rep1 C&R_Rh30_SIX4_DMSO
- GSM9118999 C&R_Rh30_SIX4_DMSO_rep2 C&R_Rh30_SIX4_DMSO
- GSM9119000 C&R_Rh30_SIX4_BI1347-24hr_rep1 C&R_Rh30_SIX4_BI1347-24…
- GSM9119001 C&R_Rh30_SIX4_BI1347-24hr_rep2 C&R_Rh30_SIX4_BI1347-24…
- GSM9119002 C&R_Rh30_SIX4_BI1347-72hr_rep1 C&R_Rh30_SIX4_BI1347-72…
- GSM9119003 C&R_Rh30_SIX4_BI1347-72hr_rep2 C&R_Rh30_SIX4_BI1347-72…
- GSM9119004 C&R_Rh30_TADA2B_DMSO_rep1 C&R_Rh30_TADA2B_DMSO
- GSM9119005 C&R_Rh30_TADA2B_DMSO_rep2 C&R_Rh30_TADA2B_DMSO
- GSM9119006 C&R_Rh30_TADA2B_BI1347-24hr_rep1 C&R_Rh30_TADA2B_BI1347-…
- GSM9119007 C&R_Rh30_TADA2B_BI1347-24hr_rep2 C&R_Rh30_TADA2B_BI1347-…
- GSM9119008 C&R_Rh30_TADA2B_BI1347-72hr_rep1 C&R_Rh30_TADA2B_BI1347-…
- GSM9119009 C&R_Rh30_TADA2B_BI1347-72hr_rep2 C&R_Rh30_TADA2B_BI1347-…
- GSM9119010 C&R_Rh30_H3K4me3_DMSO_rep1 C&R_Rh30_H3K4me3_DMSO
- GSM9119011 C&R_Rh30_H3K4me3_DMSO_rep2 C&R_Rh30_H3K4me3_DMSO
- GSM9119012 C&R_Rh30_H3K4me3_BI1347-24hr_rep1 C&R_Rh30_H3K4me3_BI1347…
- GSM9119013 C&R_Rh30_H3K4me3_BI1347-24hr_rep2 C&R_Rh30_H3K4me3_BI1347…
- GSM9119014 C&R_Rh30_H3K4me3_BI1347-72hr_rep1 C&R_Rh30_H3K4me3_BI1347…
- GSM9119015 C&R_Rh30_H3K4me3_BI1347-72hr_rep2 C&R_Rh30_H3K4me3_BI1347…
- GSM9119016 C&R_Rh30_H3K27ac_DMSO_rep1 C&R_Rh30_H3K27ac_DMSO
- GSM9119017 C&R_Rh30_H3K27ac_DMSO_rep2 C&R_Rh30_H3K27ac_DMSO
- GSM9119018 C&R_Rh30_H3K27ac_BI1347-24hr_rep1 C&R_Rh30_H3K27ac_BI1347…
- GSM9119019 C&R_Rh30_H3K27ac_BI1347-24hr_rep2 C&R_Rh30_H3K27ac_BI1347…
- GSM9119020 C&R_Rh30_H3K27ac_BI1347-72hr_rep1 C&R_Rh30_H3K27ac_BI1347…
- GSM9119021 C&R_Rh30_H3K27ac_BI1347-72hr_rep2 C&R_Rh30_H3K27ac_BI1347…
- GSM9119022 C&R_Rh30_CDK8_DMSO_rep1 C&R_Rh30_CDK8_DMSO
- GSM9119023 C&R_Rh30_CDK8_DMSO_rep2 C&R_Rh30_CDK8_DMSO
- GSM9119024 C&R_Rh30_CDK8_BI1347-24hr_rep1 C&R_Rh30_CDK8_BI1347-24…
- GSM9119025 C&R_Rh30_CDK8_BI1347-24hr_rep2 C&R_Rh30_CDK8_BI1347-24…
- GSM9119026 C&R_Rh30_CCNC_DMSO_rep1 C&R_Rh30_CCNC_DMSO
- GSM9119027 C&R_Rh30_CCNC_DMSO_rep2 C&R_Rh30_CCNC_DMSO
+ 10 more — browse all 50 samples with per-sample file links →
- GSE329566 CDK8 Inhibition Releases the Muscle Differentiation Blockade in Fusion-driven Alveolar Rhabdomyosarcoma [ChIP-Seq] 8 samples same disease briefing · shares cdk8, rhabdomyosarcoma, fusion-driven, inhibition, releases, blockade
- GSE303149 CDK8 Inhibition Releases the Muscle Differentiation Blockade in Fusion-driven Alveolar Rhabdomyosarcoma [ATAC-seq] 6 samples same disease briefing · shares cdk8, rhabdomyosarcoma, fusion-driven, inhibition, releases, blockade
- GSE303028 CDK8 Inhibition Releases the Muscle Differentiation Blockade in Fusion-driven Alveolar Rhabdomyosarcoma 104 samples same disease briefing · shares cdk8, rhabdomyosarcoma, fusion-driven, inhibition, releases, blockade
- GSE300974 CDK8 Inhibition Releases the Muscle Differentiation Blockade in Fusion-driven Alveolar Rhabdomyosarcoma [RNA-seq] 30 samples same disease briefing · shares cdk8, rhabdomyosarcoma, fusion-driven, inhibition, releases, blockade
- GSE312030 Combined inhibition of HRAS and MEK induces tumor regression and restores myogenic differentiation in HRAS-mutant rhabdomyosarcoma 159 samples same disease briefing · shares rhabdomyosarcoma, inhibition
- GSE313525 TAK1 is a key regulator of oncogenic signaling and differentiation blockade in rhabdomyosarcoma 6 samples same disease briefing · shares rhabdomyosarcoma, blockade
- GSE292876 FANCM is Required for the PAX3::FOXO1-Driven Oncogenic Program in Rhabdomyosarcoma [ChIP-Seq] 18 samples same disease briefing · shares rhabdomyosarcoma
- GSE275736 A multitargeting approach rewires cell identity in fusion-negative rhabdomyosarcoma [bulk_ATACseq] 8 samples same disease briefing · shares rhabdomyosarcoma
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.